Show simple item record

Is this the end for ranitidine? NDMA presence continues to confound

dc.contributor.authorWagner, Jennifer A.
dc.contributor.authorDinh, Jean C.
dc.contributor.authorLightdale, Jenifer R.
dc.contributor.authorGold, Benjamin D.
dc.contributor.authorColombo, Jennifer M.
dc.date2022-08-11T08:10:00.000
dc.date.accessioned2022-08-23T16:51:44Z
dc.date.available2022-08-23T16:51:44Z
dc.date.issued2021-07-01
dc.date.submitted2021-08-26
dc.identifier.citation<p>Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clin Transl Sci. 2021 Jul;14(4):1197-1200. doi: 10.1111/cts.12995. Epub 2021 May 2. PMID: 33934515; PMCID: PMC8301580. <a href="https://doi.org/10.1111/cts.12995">Link to article on publisher's site</a></p>
dc.identifier.issn1752-8054 (Linking)
dc.identifier.doi10.1111/cts.12995
dc.identifier.pmid33934515
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41915
dc.description.abstractN-nitrosodimethylamine (NDMA), a probable human carcinogen, was discovered decades ago, although elevated levels in several widely used drugs were detected only recently. Several medications that are now known to contain NDMA have remained available, whereas ranitidine has been completely withdrawn from the market. In the following paper, we discuss the overview of events that led to the withdrawal of ranitidine and compare evidence and subsequent regulatory response of other medications also containing NDMA.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33934515&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectN-nitrosodimethylamine
dc.subjectNDMA
dc.subjectranitidine
dc.subjectHealth Policy
dc.subjectPharmacy Administration, Policy and Regulation
dc.titleIs this the end for ranitidine? NDMA presence continues to confound
dc.typeJournal Article
dc.source.journaltitleClinical and translational science
dc.source.volume14
dc.source.issue4
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5754&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4721
dc.identifier.contextkey24508973
refterms.dateFOA2022-08-23T16:51:44Z
html.description.abstract<p><em>N</em>-nitrosodimethylamine (NDMA), a probable human carcinogen, was discovered decades ago, although elevated levels in several widely used drugs were detected only recently. Several medications that are now known to contain NDMA have remained available, whereas ranitidine has been completely withdrawn from the market. In the following paper, we discuss the overview of events that led to the withdrawal of ranitidine and compare evidence and subsequent regulatory response of other medications also containing NDMA.</p>
dc.identifier.submissionpathoapubs/4721
dc.contributor.departmentUMass Memorial Children's Medical Center
dc.contributor.departmentDepartment of Pediatrics, Division of Pediatric Gastroentrology
dc.source.pages1197-1200


Files in this item

Thumbnail
Name:
cts.12995.pdf
Size:
559.1Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Except where otherwise noted, this item's license is described as Copyright © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.